41 studies found for:    myeloma and carfilzomib | Open Studies
Show Display Options
Rank Status Study
1 Recruiting Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib
Conditions: Relapse Multiple Myeloma;   Refractory Multiple Myeloma
Intervention: Drug: Carfilzomib
2 Recruiting A Phase I Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed and/or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Panobinostat;   Drug: Carfilzomib;   Drug: Dexamethasone
3 Recruiting Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients
Condition: Multiple Myeloma
Intervention: Drug: CARFILZOMIB, CYCLOPHOSPHAMIDE, DEXAMETHASONE
4 Recruiting Arry-520 + Carfilzomib for Multiple Myeloma (MM)
Condition: Myeloma
Interventions: Drug: Arry-520;   Drug: Carfilzomib;   Drug: Dexamethasone;   Drug: Filgrastim
5 Recruiting Phase I/II Study of Carfilzomib in Combination With Bendamustine and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Bendamustine;   Drug: Carfilzomib;   Drug: Dexamethasone
6 Recruiting Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: carfilzomib and panobinostat
7 Recruiting Phase 3 Study With Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Condition: Multiple Myeloma
Interventions: Drug: Carfilzomib plus dexamethasone;   Drug: Velcade plus dexamethasone
8 Recruiting Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
Conditions: Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: bortezomib;   Drug: lenalidomide;   Drug: dexamethasone;   Drug: carfilzomib;   Procedure: quality-of-life assessment;   Other: laboratory biomarker analysis
9 Recruiting A Safety Study of Carfilzomib, Cyclophosphamide & Dexamethasone Prior to ASCT in Patients With Newly Diagnosed Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Carfilzomib;   Drug: Cyclophosphamide;   Drug: Dexamethasone
10 Recruiting Carfilzomib and Dexamethasone in Treating Patients With Multiple Myeloma Who Previously Underwent a Stem Cell Transplant
Conditions: Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: carfilzomib;   Drug: dexamethasone;   Other: laboratory biomarker analysis
11 Recruiting S1304, Testing Two Doses of Carfilzomib With Dexamethasone for Relapsed or Refractory Myeloma
Condition: Relapsed or Refractory Multiple Myeloma
Interventions: Drug: dexamethasone;   Drug: carfilzomib
12 Recruiting Safety, Efficacy, and Pharmacodynamics of a 60-Minute Infusion of Carfilzomib for Progressive Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Carfilzomib and Dexamethasone
13 Not yet recruiting Carfilzomib/SAHA Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant in Myeloma
Condition: Myeloma
Interventions: Drug: Carfilzomib;   Drug: SAHA;   Drug: Gemcitabine;   Drug: Busulfan;   Drug: Melphalan;   Procedure: Stem Cell Transplant (SCT);   Drug: Palifermin;   Drug: Dexamethasone;   Drug: Caphosol;   Drug: Glutamine;   Drug: Pyridoxine
14 Recruiting A Multicenter, Open-label, Phase 1b Study of Carfilzomib, Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma Subjects
Condition: Multiple Myeloma
Interventions: Drug: Carfilzomib;   Drug: Cyclophosphamide;   Drug: Dexamethasone
15 Recruiting Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
Conditions: Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
Interventions: Drug: dexamethasone;   Drug: carfilzomib;   Drug: lenalidomide;   Procedure: autologous hematopoietic stem cell transplantation;   Other: laboratory biomarker analysis
16 Recruiting Study of the Bruton's Tyrosine Kinase Inhibitor in Combination With Carfilzomib (Kyprolis™), in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma
Condition: Multiple Myeloma
Interventions: Drug: Ibrutinib;   Drug: Carfilzomib;   Drug: Placebo
17 Not yet recruiting Ph 1b, Carfilzomib, Bendamustine, Dexamethasone in Multiple Myeloma
Condition: Myeloma
Interventions: Drug: Carfilzomib;   Drug: Bendamustine;   Drug: Dexamethasone
18 Recruiting A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Vorinostat, Lenalidomide, Carfilzomib, Dexamethasone
19 Not yet recruiting Viral Protein Production After Dexamethasone, Wild-Type Reovirus, and Carfilzomib in Treating Patients With Multiple Myeloma
Condition: Refractory Multiple Myeloma
Interventions: Drug: dexamethasone;   Biological: wild-type reovirus;   Drug: carfilzomib;   Other: laboratory biomarker analysis
20 Recruiting Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation
Condition: Multiple Myeloma
Intervention: Drug: Carfilzomib

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years